anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Infants who enter foster care are at risk for developing multiple social and emotional problems later in life. These behavioral issues often result in foster children being placed with multiple different families during their childhoods. In turn, an unstable family life can lead to serious conduct disorders and mental health problems. The infants' loss of their first attachment relationship heightens the risks for developing these problems, even if the quality of care was poor prior to removal. Infants' reactions to this loss, combined with other vulnerabilities, complicate the development of new secure attachments to their foster care families. Garnering a secure attachment relationship between foster parents and foster infants may reduce the infant's risk for developing problematic mental health and conduct issues. PFR is a family therapy intervention focused on aiding foster care parents to cultivate secure attachments with their foster infants. This study will evaluate the effectiveness of the PFR program versus an EES program in promoting attachment security and infant well-being, preventing emotional and behavioral problems, countering developmental delay, and reducing placement instability in young foster care children.

Participants in this single-blind study will be randomly assigned to receive either PFR or EES. Both interventions will be administered by a trained staff member of a community agency. Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants. EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training. Outcomes will be assessed at 1, 6, and 12 months post-intervention for all participants.
Acetaminophen in massive overdosage may cause hepatic toxicity in some patients. In all cases of suspected overdose, immediately call your regional poison center or the Rocky Mountain Poison Center's toll-free number (800-525-6115) for assistance in diagnosis and for directions in the use of N-acetylcysteine as an antidote.

In adults, hepatic toxicity has rarely been reported with acute overdoses of less than 10 g and fatalities with less than 15 g. Importantly, young children seem to be more resistant than adults to the hepatotoxic effect of an acetaminophen overdose. Despite this, the measures outlined below should be initiated in any adult or pediatric patient suspected of having ingested an acetaminophen overdose.

Because clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours postingestion, liver function studies should be obtained initially and repeated at 24-hour intervals.

Consider emptying the stomach promptly by lavage or by induction of emesis with syrup of ipecac. Patients' estimates of the quantity of a drug ingested are notoriously unreliable. Therefore, if an acetaminophen overdose is suspected, a serum acetaminophen assay should be obtained as early as possible, but no sooner than 4 hours following ingestion. The antidote, N-acetylcysteine, should be administered as early as possible, and within 16 hours of the overdose ingestion for optimal results. Following recovery, there are no residual, structural, or functional hepatic abnormalities.
The study will be intiated in healthy subjects at a 1mg dose. Six subjects will be envolved in this study, and the proportion of subjects injected SY-007 to placebo is 2:1.
Unilateral moyamoya disease (MMD) represents a distinct subtype characterised by occlusive changes in the circle of Willis and abnormal vascular network formation. However, the aetiology and pathogenesis of unilateral MMD remain unclear. In this study, genetic screening of a family with unilateral MMD using whole-genome sequencing helped identify the c.1205 C > A variant of FOXM1, which encodes the transcription factor FOXM1 and plays a crucial role in angiogenesis and cell proliferation, as a susceptibility gene mutation. We demonstrated that this mutation significantly attenuated the proangiogenic effects of FOXM1 in human brain endothelial cells, leading to reduced proliferation, migration, and tube formation. Furthermore, FOXM1 c.1205 C > A results in increased apoptosis of human brain endothelial cells, mediated by the downregulation of the transcription of the apoptosis-inhibiting protein BCL2. These results suggest a potential role for the FOXM1 c.1205 C > A mutation in the pathogenesis of unilateral MMD and may contribute to the understanding and treatment of this condition.
The invention relates to destruxins A and B with glycosidase inhibiting activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. Both destruxin A and destruxin B are brown powders, wherein the destruxin A has a half-Inhibitory Concentration (IC) on alpha-glucosidase  50  ) The method comprises the following steps: 259 μg/mL; half-Inhibitory Concentration (IC) of destruxin B on alpha-glucosidase  50  ) The method comprises the following steps: 174. Mu.g/mL. The structural formulas of the destruxins A and B are respectively obtained through one-dimensional and two-dimensional nuclear magnetic resonance, accurate mass spectrum and circular dichroism identification. The destruxins A and B are obtained by culturing destruxins of Metarrhizium anisopliae, extracting and separating. The destruxin A and destruxin B can be used for preparing glycosidase inhibitors, and have the potential of treating diabetes. The preparation method adopts microbial fermentation production, is environment-friendly, is not influenced by natural environment and resources, and is easy to realize industrialized, automatic and continuous production.
PURPOSE: A method for producing bath water of fermentation enzyme used for bath, cosmetic, cleansing or moisturizing is provided to treat atopy, dermatitis, vaginosis, and rhinitis. CONSTITUTION: A method for producing bath water of fermentation enzyme comprises: a step of extracting organic component including grains, fruits and medicinal herbs; a step of inoculating useful microorganism spawn to extract; and a step of fermenting inoculated extract to obtain the bath water of fermentation enzyme. The bath water of fermentation enzyme is used as water for bath and cosmetic water. A method for extracting nutrition from medicinal herbs, grains, or fruits comprises: a step of washing medicinal herbs, grains, or fruits to remove residual agricultural chemical; a step of putting the ingredients; a step of heating at 100-120°C; a step of transferring the extract to a fermentation tank; a step of supplying cold water to a heat exchange device to reduce temperature by 30~45°C; a step of inoculating spawn of useful microorganism to the extract; a step of fermenting the extract; and a step of diluting the extract with 5-100 times of water. The useful microorganism is Saccharomyces sp. or Bacillus sp. or their mixture.
Neutrophils will be isolated from normal human volunteers and placed in cell culture with isolated hepatocytes or C3A cells (hepatoblastoma cell line that exhibit many characteristics of normal hepatocytes). These experiments will evaluate the mechanisms by which neutrophil adhere to the surface of hepatocytes, and the mechanisms by which the attached neutrophils can damage or kill the hepatocytes. Mechanisms of adhesion will involve understanding of the chemokines released by the hepatocytes that stimulate neutrophil adhesiveness, the cytokines that activate hepatocytes to express chemokines and adhesion molecules, the adhesion receptors on the neutrophil surface that are able to recognize the adhesion molecules on the hepatocyte surface, and the ability of adhesion to enhance and focus cytotoxic chemicals coming from the stimulated neutrophils. In addition, the role endotoxin can play in these sequence of events is being studies, and the specific cytotoxic mechanisms released by the neutrophils are under study. As noted in the brief summary, this grant only supports use of human cells in vitro (i.e., all experiments will be done in tissue culture). The purpose of working with this experimental model is to define what mechanisms should in future experiments be evaluated in patients with endotoxin induced disease.
Stem cell transplantation has been used for more than 50 years in the treatment of malignant and benign hematological diseases and some solid tumors. The stem cell transplant preparation process is a complex treatment that requires close follow-up in the hospital and after the transplant. Studies indicate that patients experience more intense worry and anxiety during the transplant process. Nursing care during the transplant period includes factors such as oral care, nutrition, mobilization, taking preventive measures against complications associated with neutropenia and thrombocytopenia, and these interventions have a positive effect on the patient's quality of life. Aim of this study is to determine the effect of the mobile application on quality of life and supportive care in patient undergoing stem cell transplantation. In the study, patients will be randomized into the group in which standard processes are applied and the group trained by the mobile application. Functional assessment scale (FACT-BMT), James Supportive Care and Needs Assessment Scale in Cancer Patients and Hospital Anxiety and Depression Scale were planned to be administered to both groups on the day of hospitalization and discharge day, and 3rd month follow up. The mobile application content will consist of 3 modules: information about the stem cell transplantation process, stem cell transplantation and nutrition, lifestyle recommendations, and answering possible questions of the patients and their relatives. At the end of the study, the test results of the patient groups will be compared both within themselves and with each other. The effects of standard and mobile application training on the test results of the patients and whether the results of the group receiving mobile application training differ from the standard training group will be investigated.
Participants in the wait list control group undergo an initial assessment but receive no active intervention for 10 weeks. After 10 weeks, these patients undergo post-treatment assessment and are offered the opportunity to either enter group treatment in an eating disorders program or enter other appropriate treatment. Three-month follow-up data are not collected from these individuals.
PURPOSE: To enable the fixation to a separate highly glycosilated final product in a protein specimen during glycosylation by making a structure of 2-furoyl-4 (5) (2-furanyl)-1H-imidazole strongly similar to the center structure of a chromophoric group in a fluorescent dye. CONSTITUTION: Many sequences such that two glucose molecules and two lysine ε-amino groups act mutually to form a tetra-substituted imidazole system are shown. In a route A, a compd. acts on a keto group of lysine ε-fructosylisine residue and subsequently cyclized with second glucose molecules. In a route B, two fructosylisines act on cyclization. The possibility of a route C is proposed by the observation on a product preserving glucose by valine until now and valine has two acted sugar residues. Both of the routes A, C wherein a fructosylisine group generates mutual action along with a separate amino group can confirm the bonding of protein to other protein already performing non- enzymatic browning.
A rectal mucosal administration preparation of  Pulsatilla chinensis  (Bge.) Regel saponin B4 contains  Pulsatilla chinensis  (Bge.) Regel saponin B4 and a pharmaceutically acceptable substrate. The drug preparation is a rectal gel or a rectal suppository. Compared with oral administration, the rectal mucosal administration preparation of  Pulsatilla chinensis  (Bge.) Regel saponin B4 has a lower effective dose, and has a better medicinal effect at the same dose.
The present invention encompasses prostaglandin E 2  (PGE 2 ) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E 2  and neutralize prostaglandin E 2  activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E 2  and for inhibiting prostaglandin E 2  activity, e.g., in a human subject suffering from a disorder in which prostaglandin E 2  activity is detrimental.
In the first week, 500 mg of metformin was administered in the morning. In the second week, the dosage was revised to 500 mg of metformin in the morning and the placebo in the evening. During metformin intervention period, the clozapine dose remained unchanged in these recruited clozapine-treated patients.
Fibromyalgia diagnostic method based on micrornas. The invention provides a method for the molecular diagnosis of fibromyalgia patients, based on the analysis of the possible alteration of the levels of certain micrornas in peripheral blood mononuclear cells. The method comprises the analysis of mirna levels mir223, mir-451, mir-338, mir-143 and mir-145 and the diagnosis of fibromyalgia when at least one or, preferably, several of them have decreased levels with respect to a reference value, which is preferred to be the level of each microrna in healthy individuals. Three additional micrornas, mir-21, mir-1260b and mir-1908, are also provided, which can be used as a negative control to confirm the diagnosis. The method facilitates an objective diagnosis of fibromyalgia, based on molecular markers that are determined from a sample that is easy to obtain and process, such as blood. (Machine-translation by Google Translate, not legally binding)
Protective vaccines against communicable diseases are of major importance in patients with autoimmune diseases or impaired immune response. In patients with multiple sclerosis bacterial or viral infections may lead to disease progression and vaccines can protect from these infections and prevent disease progression. Fear of possible side effects of vaccines have led to a general restraint regarding vaccination of patients with MS. However, previous studies have not shown an increased risk of disease progression following Hepatitis B vaccination and even a reduced progression rate in relapsing-remitting MS after tetanus/diphtheria vaccination.

Various disease modifying treatments (DMT) are available for MS, most of these therapies lead to an impairment of the immune system affecting the immune response to vaccination. Additionally, live attenuated vaccines may lead to severe side-effects if used in patients under DMT treatment. Testing immune response after vaccination may be prudent in subjects undergoing DMT to assure vaccination success since only a limited number of studies have investigated immune response after vaccination in patients with MS undergoing DMT.
Buspirone hydrochloride tablets, USP are an antianxiety agent that is not chemically or pharmacologically related to the benzodiazepines, barbiturates, or other sedative/anxiolytic drugs.

Buspirone hydrochloride is a white crystalline, water soluble compound with a molecular weight of 421.96. Chemically, buspirone hydrochloride is N-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,1-cyclopentanediacetamide monohydrochloride. The empirical formula C21H31N5O2•HCl is represented by the following structural formula:

Each tablet, for oral administration, contains 10 mg of buspirone hydrochloride, USP (equivalent to 9.1 mg of buspirone free base, respectively). The 10 mg tablets are scored so they can be bisected. Thus, the 10 mg tablet can provide a 5 mg dose. Buspirone hydrochloride tablets, USP contain the following inactive ingredients: anhydrous lactose, colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.
Patients receive ATN-161 IV over 10 minutes 3 times weekly in weeks 1-6 and carboplatin IV over 20 minutes in week 3 during course 1. Beginning in course 2, patients receive carboplatin IV over 20 minutes in week 1 and ATN-161 IV over 10 minutes 3 times weekly in weeks 1-4. Treatment repeats every 4 weeks in the absence of disease progression or unacceptable toxicity.
FIELD: biochemistry. SUBSTANCE: method involves preparing a mixture of free reagent with nucleic acids. Each nucleic acid is bound with the first reagent. Then interaction of the mixture with free reagent is carried out and reaction products are separated by capability of free reagent to change its properties. Invention can be used for identification of compounds, in part, nucleic acids. EFFECT: improved method of identification. 23 cl, 15 dwg, 1 tbl
Novel methods and systems for increasing the pH of a composition applied to the teeth and/or gums are disclosed. The composition is gellable under the influence of a pH change. The pH change is typically a pH increase in the case where the pH directly triggers gelation. The pH change is generally a pH decrease in the case of gelation induced by ions (e.g., calcium ions) released from the pH sensitive carrier. The device comprises a dispensing unit for the composition, the distal end of which is adapted to apply the substance to the teeth or gums. The device further comprises an electrode system comprising a first electrode and a second electrode, the first electrode being adapted to be held in contact with the aqueous liquid composition at a location at or near the tooth or gum and the second electrode being adapted to be held in contact with the aqueous liquid composition at a location remote from the tooth or gum, the electrode system being adapted to provide a potential difference of 1.5 to 10 volts between the electrodes.
Provides a compound Caffarolide A, a pharmaceutical composition thereof and application thereof in pharmacy, belonging to the technical field of medical food. The preparation method of the Caffarolide A compound has the advantages of easily available raw materials, easy operation and high yield, and is suitable for industrial production. The pharmaceutical composition with the Caffarolide A as the active ingredient provides a product with better medicinal effect for new lipid-lowering drugs. From the results of cell viability assay, caffarolide A still showed no cytotoxicity at 100. Mu.M concentration, indicating that it has a wider activity window. At a concentration of 40. Mu.M, lipid droplets had clearly disappeared and very little remained. The compound Caffarolide A can be applied to the preparation of 3T3-L1 preadipocyte lipid inhibitory active agents, lipid-lowering drugs and drugs for treating obesity diseases, and can be used for preparing lipid-lowering health products.
BACKGROUND: Weight estimation is required in adult patients when weight-based medication must be administered during emergency care, as measuring weight is often impossible. Inaccurate estimations may lead to inaccurate drug doses, which may cause patient harm. Little is known about the relative accuracy of different methods of weight estimation that could be used during resuscitative care. The aim of this study was to evaluate the performance and suitability of existing weight estimation methods for use in adult emergency care.
METHODS: A systematic literature search was performed for suitable articles that studied the accuracy of weight estimation systems in adults. The study characteristics, the quality of the studies, the weight estimation methods evaluated, the accuracy data, and any information on the ease-of-use of the method were extracted and evaluated.
RESULTS: A total of 95 studies were included, in which 27 different methods of total body weight estimation were described, with 42 studies included in the meta-analysis. The most accurate methods, determined from the pooled estimates of accuracy (the percentage of estimates within 10% of true weight, with 95% confidence intervals) were 3-D camera estimates (88.8% (85.8 to 91.8%)), patient self-estimates (88.7% (87.7 to 89.7%)), the Lorenz method (77.5% (76.4 to 78.6%)) and family estimates (75.0% (71.5 to 78.6%)). However, no method was without significant potential limitations to use during emergency care.
CONCLUSION: Patient self-estimations of weight were generally very accurate and should be the method of choice during emergency care, when possible. However, since alternative estimation methods must be available when confused, or otherwise incapacitated, patients are unable to provide an estimate, alternative strategies of weight estimation should also be available.
PROBLEM TO BE SOLVED: To obtain a new compound composed of a specific nitrogen-containing heterocyclic compound, having cGMP phosphodiesterase inhibiting activities, and useful for prevention or treatment of ischemic heart disease, angina pectoris, hypertension, cardiac failure, asthma or the like. SOLUTION: This new compound is the one of formula I (R1 to R3 are each H, a halogen, a lower alkyl or the like; R5 is H, OH, hydrazino or the like; R6 is H, amino, a lower alkyl or the like), e.g. 2-chloro-8-(3,4- methylenedioxybenzyl)aminopyrido[2,3-d]pyrimidine. The compound of formula I is obtained by allowing phosphorus oxychloride to act on a pyridopyrimidine derivative of formula II (R5a is H, a halogen or a group directly bonding to the pyridopyrimidine skeleton with a carbon atom), or allowing the phosphorus oxychloride to act thereon in the presence of phosphorus pentoxide, and heating the product. When the compound of formula I is orally administered, one to three doses of 10-100 mg/adult are preferably administered per day. In the case of injection, the amount is preferably 3-1,000 μg/kg.
PURPOSE: Postmastectomy radiation therapy is a mainstay in the adjuvant treatment of node-positive breast cancer, but it poses risks for women with breast reconstruction. Multibeam intensity-modulated radiation therapy improves dose conformality and homogeneity, potentially reducing complications in breast cancer patients with implant-based reconstruction. To investigate this hypothesis, we conducted a single-arm phase 2 clinical trial of breast cancer patients who underwent mastectomy/axillary dissection and prosthesis-based reconstruction.
METHODS AND MATERIALS: The primary endpoint was the rate of implant failure (IF) within 24 months of permanent implant placement, which would be considered an improvement over historical controls if below 16%. IF was defined as removal leading to a flat chest wall or replacement with another reconstruction. Patients were analyzed in 2 cohorts. Cohort 1 (RT-PI) received radiation therapy to the permanent implant. Cohort 2 (RT-TE) received radiation therapy to the TE. IF rates, adverse events, and quality of life were analyzed. Follow-up/postradiation therapy assessments were compared with the baseline/preradiation therapy assessments at 3 to 10 weeks after exchange surgery. A subgroup underwent serial magnetic resonance imaging (MRI) sessions to explore the association between MRI-detected changes and capsular contracture, a known adverse effect of radiation therapy.
RESULTS: Between June 2014 and March 2017, 119 women were enrolled. Cohort 1 included 45 patients, and cohort 2 had 74 patients. Among 100 evaluable participants, 25 experienced IF during the study period. IF occurred in 8/42 (19%) and 17/58 (29%) in cohorts 1 and 2, respectively. Among the IFs, the majority were due to capsular contracture (13), infection (7), exposure (3), and other reasons (2). Morphologic shape features observed in longitudinal MRI images were associated with the development of Baker grade 3 to 4 contractures.
CONCLUSIONS: The rate of IF in reconstructed breast cancer patients treated with intensity-modulated radiation therapy was similar to, but not improved over, that observed with conventional, 3-dimensional-conformal methods. MRI features show promise for predicting capsular contracture but require validation in larger studies.